Infectious Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others), By End Use (Hospitals, Clinics, Others), By Region, and By Competition, 2020-2030F

Market Overview

The Global Infectious Disease Therapeutics Market, valued at USD 67.64 Billion in 2024, is projected to experience a CAGR of 7.74% to reach USD 105.80 Billion by 2030. The Global Infectious Disease Therapeutics Market encompasses pharmaceutical agents and medical interventions designed for the prevention, treatment, and management of illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites. Key drivers supporting market expansion include the increasing global prevalence of infectious diseases, the persistent challenge of antimicrobial resistance, and growing investments in research and development to address unmet medical needs. Further impetus comes from continuous advancements in diagnostic technologies enabling earlier and more precise disease identification.

According to PhRMA, in 2024, the U. S. Food and Drug Administration approved 59 novel treatments and vaccines across various therapeutic areas, with advancements in infectious disease threats specifically highlighted. Similarly, according to EFPIA, infectious diseases were among the therapeutic areas collectively accounting for 44-47% of Phase 1 clinical trials initiated in 2023, reflecting a sustained research and development focus. A significant challenge impeding market growth remains the substantial costs associated with drug discovery and development, coupled with lengthy and stringent regulatory approval processes.

Key Market Drivers

The increasing global burden of infectious diseases fundamentally drives market expansion, creating persistent and widespread demand for effective treatments and preventative measures. Diseases like tuberculosis and malaria continue to exact a significant toll on global health, necessitating ongoing research and development into novel pharmacological agents and improved therapeutic strategies. The sheer scale of these challenges ensures a consistent market for diagnostics, drugs, and vaccines, as healthcare systems grapple with endemic infections and outbreaks. According to the World Health Organization, in its Global Tuberculosis Report 2023, an estimated 10.6 million people fell ill with tuberculosis worldwide in 2022, underscoring the critical need for continued therapeutic interventions. This sustained disease pressure compels pharmaceutical companies to invest in developing new therapies to address unmet medical needs.

The rising prevalence of antimicrobial resistance (AMR) is a profound accelerator for the infectious disease therapeutics market, demanding continuous innovation to circumvent diminishing treatment efficacy. As pathogens evolve resistance to existing drugs, the development pipeline must deliver novel antibiotics, antivirals, and antifungals to maintain effective treatment options. This imperative to overcome resistance mechanisms spurs significant investment in drug discovery, particularly for high-priority pathogens. The challenges of AMR are evident in new drug approvals; according to the World Health Organization, in its October 2023 report titled "Antibacterial agents in clinical and preclinical development: an overview and analysis of the 2023 pipeline," only 12 new antibacterial agents have been approved since 2017. This underscores the urgent need for robust research, a need further supported by substantial public funding. According to the National Institutes of Health, in their Congressional Justification for Fiscal Year 2024, the budget for the National Institute of Allergy and Infectious Diseases (NIAID) for fiscal year 2023 was approximately $6.3 billion, demonstrating significant investment in this crucial therapeutic area.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the Global Infectious Disease Therapeutics Market is the substantial costs associated with drug discovery and development. Bringing new pharmaceutical agents from initial research to market approval demands extensive financial outlays for preclinical studies, multiple phases of clinical trials, and manufacturing infrastructure. This immense capital requirement significantly raises the barrier to entry for innovators and imposes considerable financial risk on companies, influencing strategic decisions about which therapeutic areas to prioritize.

These high development costs directly hamper market expansion by limiting the number of novel infectious disease treatments that can be advanced. Pharmaceutical companies must allocate vast resources, and the failure rate of compounds in development means that a large portion of this investment does not result in a marketable product. According to EFPIA, in 2023, the research-based pharmaceutical industry invested an estimated €50,000 million in research and development in Europe, reflecting the considerable financial commitment required to innovate in this sector. This continuous, large-scale expenditure diverts funds from other potential projects, thereby reducing the overall pipeline of new infectious disease therapeutics.

Key Market Trends

The application of Artificial Intelligence (AI) in drug discovery is significantly reshaping the development landscape for infectious disease therapeutics. AI algorithms are increasingly employed to accelerate the identification of novel drug targets, optimize compound synthesis, and predict drug efficacy and toxicity with greater precision and speed, thereby reducing the time and cost associated with traditional drug development. This technological integration is poised to streamline the discovery of urgently needed treatments for evolving pathogens. According to a survey from Rackspace Technology and Dell/VMware, conducted in October 2023, two out of three pharmaceutical companies (67%) planned to increase their investment in information technology, including artificial intelligence, over the subsequent 12 months. This substantial industry-wide commitment to AI is expected to catalyze innovation across all therapeutic areas, including infectious diseases, by enhancing the efficiency of research and development pipelines.

The evolution of next-generation vaccine technologies represents another pivotal trend, focusing on developing more effective, durable, and rapidly deployable prophylactic solutions for infectious diseases. This encompasses advancements in mRNA-based vaccines, viral vector platforms, and subunit vaccines designed to provide broader protection or address emerging threats more swiftly. Such innovations are critical for enhancing global health security and reducing the burden of infectious diseases. A notable example of progress in advanced preventative therapeutics, which aligns with next-generation technologies, was reported at AIDS24 in July 2024: data from the PURPOSE 1 trial indicated that Gilead's lenacapavir for HIV pre-exposure prophylaxis (PrEP) was 89% more effective than Truvada, reducing HIV infections by 96% compared to background HIV incidence. These advancements underscore the continuous innovation in developing highly effective preventative measures, moving beyond traditional vaccine paradigms to safeguard public health.

Segmental Insights

The Hospitals segment is emerging as the fastest growing within the Global Infectious Disease Therapeutics Market, primarily owing to its crucial role as the initial point of care for patients with diverse infections. This significant growth is further driven by the rising prevalence of infectious diseases, including hospital-acquired infections, coupled with an expanding geriatric population that is inherently more susceptible to severe health complications. Hospitals provide extensive patient management, necessitating specialized therapeutics, such as intravenous antibiotics, which are often administered and managed exclusively through hospital pharmacies for effective treatment and rigorous infection control.

Regional Insights

North America leads the Global Infectious Disease Therapeutics Market due to its robust and well-established healthcare infrastructure, which facilitates extensive patient access to advanced treatments. The region benefits from substantial investments in research and development, fostering innovation and the creation of novel therapies. Furthermore, a supportive regulatory environment, including agencies like the U. S. Food and Drug Administration, expedites the approval and commercial availability of new anti-infective agents. This, combined with the strong presence of major pharmaceutical companies and advanced diagnostic capabilities, underpins North America's dominance in combating infectious diseases.

Recent Developments

• In October 2025, Spero Therapeutics, Inc., in collaboration with GSK, is scheduled to present late-breaking Phase 3 trial results for tebipenem HBr at IDWeek 2025. These results stem from the PIVOT-PO study, which evaluated the efficacy and safety of tebipenem HBr as an investigational oral carbapenem for complicated urinary tract infections (cUTIs), including pyelonephritis. The presentation will detail findings from the successful trial, reinforcing the potential of this therapy to offer a much-needed oral treatment option for patients facing multi-drug resistant bacterial infections in both community and hospital settings.

• In August 2025, Iterum Therapeutics plc commercially launched ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets in the United States. This marks the availability of the first oral penem antibiotic in the U.S. and the first new branded product for uncomplicated urinary tract infections (uUTIs) in over 25 years. The U.S. Food and Drug Administration had approved ORLYNVAH™ in October 2024 for adult women with uUTIs caused by specific bacteria, particularly when alternative oral antibacterial options are limited. This launch addresses the increasing antimicrobial resistance observed in common outpatient infections.

• In December 2024, Gilead Sciences Inc. received significant recognition for its breakthrough in infectious disease therapeutics. Its drug, lenacapavir, was named a "Breakthrough of the Year" by *Science* magazine. Clinical trials demonstrated lenacapavir's 100% efficacy in preventing HIV transmission in cisgender African women and 99.9% efficacy in men and gender-diverse individuals when administered twice annually. These pivotal trial results were published in *The New England Journal of Medicine* and presented at a major international AIDS society meeting, highlighting a substantial advance in long-acting pre-exposure prophylaxis for HIV.

• In July 2024, Evotec SE announced a multi-year master research collaboration and licensing agreement with Pfizer. This partnership is strategically focused on early discovery research within the metabolic and infectious disease areas. The collaborative research activities are being conducted at Evotec's facilities in France, which include specialized capabilities in high-throughput screening and *in vitro* and *in vivo* biology. Evotec is set to receive research support funding from Pfizer, alongside potential milestone payments and royalties, aiming to identify novel first-in-class therapeutic approaches for pervasive global health challenges.

Key Market Players

• Novartis AG
• Gilead Sciences Inc
• GSK PLC
• Johnson & Johnson Innovative Medicine
• F Hoffmann-La Roche AG
• BioCryst Pharmaceuticals Inc
• Merck & Co Inc
• Boehringer Ingelheim International GmbH

Report Scope:

In this report, the Global Infectious Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Infectious Disease Therapeutics Market, By Disease Type:

o   HIV

o   Hepatitis

o   Influenza

o   TB

o   Malaria

o   HPV

o   Others

• Infectious Disease Therapeutics Market, By End Use:

o   Hospitals

o   Clinics

o   Others

• Infectious Disease Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Infectious Disease Therapeutics Market.

Available Customizations:

Global Infectious Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Infectious Disease Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]